These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 19808125

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
    Morgan CL, Evans M, Toft AD, Jenkins-Jones S, Poole CD, Currie CJ.
    Clin Ther; 2011 Jan; 33(1):27-35. PubMed ID: 21397771
    [Abstract] [Full Text] [Related]

  • 5. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R.
    Clin Ther; 2005 Jan; 27 Suppl B():S75-88. PubMed ID: 16519039
    [Abstract] [Full Text] [Related]

  • 6. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
    McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A.
    Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
    [Abstract] [Full Text] [Related]

  • 7. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS, BOOST: Intensify All Trial Investigators.
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [Abstract] [Full Text] [Related]

  • 8. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M, Swatko A, Hilberg C, Shestakova M.
    Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
    [Abstract] [Full Text] [Related]

  • 9. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G.
    J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results.
    Nobels F, D'Hooge D, Crenier L.
    Curr Med Res Opin; 2012 Jun; 28(6):1017-26. PubMed ID: 22612579
    [Abstract] [Full Text] [Related]

  • 17. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [Abstract] [Full Text] [Related]

  • 18. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 19. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLog Mix-vs.-Exenatide Study Group.
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.